<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00894959</url>
  </required_header>
  <id_info>
    <org_study_id>HEPSBCCV0109_BLA1</org_study_id>
    <secondary_id>Heparin Blausiegel 1</secondary_id>
    <secondary_id>(Version 8)</secondary_id>
    <nct_id>NCT00894959</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sodium Heparin in Patients</brief_title>
  <official_title>Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is verify, through a randomized, single-blind, multicentre,
      parallel and comparative study, the effectiveness of heparin sodium of porcine origin in
      patients undergoing heart surgery at that require the aid of cardiopulmonary bypass, through
      the control of hemostasis during and after surgery, based on the strengths of markers of
      coagulation TCA, TTPA, Anti-Xa, heparin bioavailable and loss of excessive blood (bleeding)
      at the end of the surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of TTPA, Anti-Xa and ACT</measure>
    <time_frame>Pre - Operative (T0) Pre Heparinization (T1) Top of Extracorporeal (T2) Period Intraoperative (T3) Termination Extracorporeal (T4) Postoperative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of bleeding</measure>
    <time_frame>Pre - Operative (T0) Pre Heparinization (T1) Top of Extracorporeal (T2) Period Intraoperative (T3) Termination Extracorporeal (T4) Postoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>Pre - Operative (T0) Pre Heparinization (T1) Top of Extracorporeal (T2) Period Intraoperative (T3) Termination Extracorporeal (T4) Postoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heparin Sodium Blausiegel 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>heparin sodium - APP 5.000 USP</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Heparin sodium Blausiegel 1</intervention_name>
    <description>Heparin sodium Blausiegel 1 5.000 UI</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Heparin sodium APP</intervention_name>
    <description>Heparin sodium APP 5.000 USP</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who agree with all aspects of the study and sign the FICT;

          -  Patients of both sexes;

          -  Patients aged above 18 years;

          -  Patients with cardiac surgery and requiring movement; AND

          -  Extracorporeal.

        Exclusion Criteria:

          -  Patients with hematological disorders that compromise the surgical changes (eg
             myeloproliferative syndromes, anemia Hb &lt;11.0 g / dL,

          -  Platelets &lt; 150,000 mm3);

          -  Patients with disorders of hemostasis (INR&gt; 1.40) (rTTPA&gt; 1.40);

          -  Patients with renal dysfunction (creatinine&gt; 1.50);

          -  Patients with deep hyperthermia;

          -  Liver disease (AST and ALT&gt; 2 times that of the reference value);

          -  Patients with a history of allergy to heparin or protamine;

          -  Patients with history of heparin-induced thrombocytopenia;

          -  Tables infection (eg endocarditis, infection of immune human (HIV), hepatitis B and C,
             septicemia and pneumonia);

          -  Reoperations;

          -  Use of antiplatelet (clopidogrel and ticlopidine) for less than 7 days;

          -  Use of acetylsalicylic acid is less than 5 days;

          -  Use of low molecular weight heparin for less than 24 hours; OR

          -  Use of non-fractioned heparin for less than 12 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LAL clinica pesquisa e desenvolvimento ltda</name>
      <address>
        <city>Valinhos</city>
        <state>SP</state>
        <zip>13270000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2009</study_first_submitted>
  <study_first_submitted_qc>May 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2009</study_first_posted>
  <last_update_submitted>February 22, 2013</last_update_submitted>
  <last_update_submitted_qc>February 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2013</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Frederico</name_title>
    <organization>LAL Cl√≠nica Pesquisa e Desenvolvimento Ltda</organization>
  </responsible_party>
  <keyword>heparin cardiac surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

